Close
Achema middle east
swop processing & packaging

Veristat to Assist on Adaptive Enrichment Trial for Verastem’s Defactinib in Mesothelioma

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

ACHEMA 2027: Global Forum for Pharma and Life Sciences

ACHEMA 2027 sets an even stronger focus on innovations...

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

Veristat LLC. a leading Boston-based clinical research organization today announced its advisory role on the implementation of an adaptive enrichment trial design for Verastem Inc. . The enhanced design aims to optimize the current trial of defactinib a novel small molecule inhibitor of focal adhesion kinase (FAK) in patients with malignant pleural mesothelioma.

“We have identified a biomarker in mesothelioma that may predict increased sensitivity to defactinib” said Dr. Joanna Horobin Chief Medical Officer at Verastem. “We felt strongly that the application of an enrichment design would help us to accelerate the program to a potential regulatory decision. We are excited to have Veristat’s experience in enrichment trial design and execution supporting this trial.”

Veristat’s input on the overall trial design as well as the adaptive enrichment design architecture and planned analyses will help facilitate decisions required at key development intersections of the program.

“The Verastem clinical development team has taken a dynamic approach to the design of this study” commented Dr. John Balser President at Veristat. “Our team at Veristat will be assisting them with the statistical and operational challenges inherent in the adaptive enrichment design architecture. Our goal is to produce a trial that will quickly and cost effectively yield the highest likelihood of success for their target patient population.”

About Veristat

Bringing 20 years of experience to its clients Veristat is a clinical research organization (CRO) that supports pharmaceutical biotechnology and medical device companies through every phase of the clinical trial process as well as the preparation of integrated summary documents and submission-ready CDISC data for regulatory filings. Visit www.veristat.com.

 

 

 

Latest stories

Related stories

ACHEMA 2027: Global Forum for Pharma and Life Sciences

ACHEMA 2027 sets an even stronger focus on innovations...

Amcor to showcase responsible and patient-centric packaging innovations at CPHI Frankfurt 2025

User-friendly solutions designed to enhance convenience, performance and patient...

Kadans Science Partner secures one of the most significant deals in Glasgow of H1 2025

Chemify scales up operations at Health Innovation Hub Digital...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »